Perseus Proteomics Inc. Logo

Perseus Proteomics Inc.

Develops antibody-based therapeutics, diagnostics, and research support services.

4882 | T

Overview

Corporate Details

ISIN(s):
JP3836800007
LEI:
Country:
Japan
Address:
目黒区駒場四丁目7番6号

Description

Perseus Proteomics Inc. is a drug discovery biotechnology company specializing in the development of novel antibody-based therapeutics and diagnostics. Originating from the University of Tokyo, the company leverages proprietary antibody technologies and screening platforms to create a pipeline of drug candidates targeting cancer and other diseases. Its business is structured into three main segments: Drug Discovery, which focuses on its internal pipeline; Antibody Research Support, offering services to the research community; and Antibody/Reagent Sales, which provides products like ELISA kits. The company aims to contribute to global healthcare through its advanced antibody-based solutions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2023-06-23 08:03
有価証券報告書-第23期(2022/04/01-2023/03/31)
Japanese 2.7 MB
2023-02-13 07:06
確認書
Japanese 8.1 KB
2023-02-13 07:05
四半期報告書-第23期第3四半期(2022/10/01-2022/12/31)
Japanese 134.3 KB
2022-11-11 07:14
四半期報告書-第23期第2四半期(令和4年7月1日-令和4年9月30日)
Japanese 163.0 KB
2022-11-11 07:14
確認書
Japanese 8.2 KB
2022-08-12 08:08
確認書
Japanese 8.2 KB
2022-08-12 08:07
四半期報告書-第23期第1四半期(令和4年4月1日-令和4年6月30日)
Japanese 126.0 KB
2022-06-23 05:52
内部統制報告書-第22期(令和3年4月1日-令和4年3月31日)
Japanese 21.3 KB
2022-06-23 05:51
確認書
Japanese 8.2 KB
2022-06-23 05:50
有価証券報告書-第22期(令和3年4月1日-令和4年3月31日)
Japanese 2.7 MB
2022-02-14 07:22
四半期報告書-第22期第3四半期(令和3年10月1日-令和3年12月31日)
Japanese 160.0 KB
2021-11-12 07:08
四半期報告書-第22期第2四半期(令和3年7月1日-令和3年9月30日)
Japanese 175.3 KB
2021-08-13 08:05
四半期報告書-第22期第1四半期(令和3年4月1日-令和3年6月30日)
Japanese 147.3 KB
2021-06-25 08:23
確認書
Japanese 8.8 KB
2021-06-25 08:20
有価証券報告書-第21期(令和2年4月1日-令和3年3月31日)
Japanese 2.7 MB

Automate Your Workflow. Get a real-time feed of all Perseus Proteomics Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Perseus Proteomics Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Perseus Proteomics Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.